Analysts have been eager to weigh in on the Healthcare sector with new ratings on GW Pharma (GWPH), Perrigo Company (PRGO) and Applied Molecular Transport (AMTI).
GW Pharma (GWPH)
In a report issued on February 19, Danielle Brill from Raymond James maintained a Hold rating on GW Pharma. The company’s shares closed last Friday at $213.81, close to its 52-week high of $217.50.
According to TipRanks.com, Brill is a 4-star analyst with an average return of 17.7% and a 54.8% success rate. Brill covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Sarepta Therapeutics, and SAGE Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for GW Pharma with a $217.13 average price target, which is a 1.6% upside from current levels. In a report issued on February 4, H.C. Wainwright also downgraded the stock to Hold with a $220.00 price target.
See today’s analyst top recommended stocks >>
Perrigo Company (PRGO)
In a report released yesterday, Elliot Wilbur from Raymond James maintained a Hold rating on Perrigo Company. The company’s shares closed last Friday at $42.10, close to its 52-week low of $40.01.
According to TipRanks.com, Wilbur is a 1-star analyst with an average return of -0.5% and a 47.4% success rate. Wilbur covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Amneal Pharmaceuticals, and Flexion Therapeutics.
Perrigo Company has an analyst consensus of Hold, with a price target consensus of $49.00.
Applied Molecular Transport (AMTI)
In a report released today, Joseph Schwartz from Leerink Partners maintained a Buy rating on Applied Molecular Transport, with a price target of $74.00. The company’s shares closed last Friday at $64.47, close to its 52-week high of $67.45.
According to TipRanks.com, Schwartz is a 5-star analyst with an average return of 20.5% and a 53.4% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, KalVista Pharmaceuticals, and Aurinia Pharmaceuticals.
Currently, the analyst consensus on Applied Molecular Transport is a Moderate Buy with an average price target of $74.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.